+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07855965

Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer A Multicenter Phase II Study

Led by West China Hospital · Updated on 2026-10-02

40

Participants Needed

9

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new neoadjuvant treatment approach for patients with resectable stage IB to IIIB non-small cell lung cancer NSCLC. This prospective Phase II study aims to assess the effectiveness and safety of combining CT-guided Cryo-Thermal Ablation with toripalimab and platinum-based doublet chemotherapy before surgery. The study focuses on improving major pathological response rates since many patients currently do not achieve a complete response with chemoimmunotherapy alone. Participants will first undergo a CT-guided Cryo-Thermal Ablation procedure targeting the primary lung tumor. After that, they will receive three planned cycles of toripalimab, an anti-PD-1 monoclonal antibody, combined with platinum-based doublet chemotherapy administered every three weeks. Following these treatments, patients will have a preoperative reassessment before undergoing curative-intent surgical removal of the tumor. The study includes about 40 participants and is conducted across multiple centers. During the trial, participants will be closely monitored through pathological evaluations of surgical specimens, imaging assessments, and health-related quality of life questionnaires. Researchers will measure outcomes such as pathological complete response rate, major pathological response rate, objective response rate, event-free survival, overall survival, and treatment-emergent adverse events. Additional exploratory analyses will examine immune responses and molecular changes using advanced genomic and proteomic techniques. The total follow-up period may extend up to approximately five years to assess long-term outcomes.

CONDITIONS

Brief Title

Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer

Research Team

B

Beinuo Wang, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here